Thailand Cannabis Recriminalization: Policy Reversal and Legal Changes

Executive Summary

Thailand is poised to reverse its landmark 2022 cannabis decriminalization, with a draft bill now advancing through parliament that would restrict cannabis to medical use only and recriminalize recreational possession and consumption. The proposed legislation, which surfaced in August 2026, marks a dramatic policy reversal for the first Asian nation to decriminalize cannabis at the national level. Under the draft framework, recreational cannabis would once again become a controlled substance, with criminal penalties reinstated for non-medical use. The bill would establish a medical-only licensing regime overseen by the Food and Drug Administration (FDA) and Ministry of Public Health, effectively shutting down the thousands of dispensaries, cafes, and cultivation operations that emerged during Thailand's brief experiment with open cannabis commerce. The recriminalization effort reflects sustained political pressure from conservative factions, public health officials concerned about youth access, and tourism industry stakeholders who have raised alarm about Thailand's international image. If enacted, the legislation would represent one of the most significant cannabis policy reversals in modern history, with profound implications for Southeast Asian drug policy, the global cannabis industry, and the estimated 5,000-10,000 businesses that entered Thailand's cannabis market between 2022 and 2026.

Why This Matters

Thailand's recriminalization effort affects millions of patients, thousands of businesses, and the trajectory of cannabis reform across Asia. The policy reversal directly impacts an estimated 1.2 million Thai citizens who have accessed cannabis products since decriminalization, including medical patients using cannabis for chronic pain, cancer treatment side effects, and neurological conditions. The economic stakes are substantial: Thailand's cannabis industry generated an estimated $1.2 billion in revenue in 2025, supporting between 5,000 and 10,000 registered businesses and an estimated 50,000 jobs across cultivation, retail, processing, and tourism sectors.

International investors have committed hundreds of millions of dollars to Thai cannabis ventures since 2022, including multi-state operators (MSOs) from North America seeking Asian market entry points. Major Canadian licensed producers established cultivation partnerships, while U.S.-based ancillary service providers opened regional headquarters in Bangkok. Recriminalization would likely trigger significant capital losses and potential legal disputes over regulatory takings.

Beyond Thailand's borders, the policy shift carries regional significance. Thailand's 2022 decriminalization inspired cannabis reform discussions in Malaysia, the Philippines, and South Korea. A reversal could embolden prohibitionist forces across Southeast Asia and complicate efforts to reform outdated drug policies rooted in the 1961 Single Convention on Narcotic Drugs. The United Nations Office on Drugs and Crime (UNODC) has monitored Thailand's experiment closely as a potential model for harm reduction approaches in the region.

Public health stakeholders have raised concerns about disruption to legitimate medical access. An estimated 200,000 Thai patients hold medical cannabis registrations through the Ministry of Public Health, and abrupt recriminalization could force these individuals back to pharmaceutical alternatives or underground markets. Patient advocacy organizations have warned that restrictive medical frameworks may exclude conditions currently treated with cannabis, particularly mental health applications not yet supported by Thailand's conservative medical establishment.

Background and History: From Decriminalization to Reversal

Thailand's cannabis policy has undergone three distinct phases since 2018, moving from strict prohibition to full decriminalization and now toward medical-only recriminalization.

Traditional Use and Modern Prohibition (Pre-2018)

Cannabis has a centuries-long history in traditional Thai medicine, where it was used to treat pain, digestive ailments, and fatigue. Thai stick, a potent cannabis preparation bound to bamboo sticks, gained international notoriety during the Vietnam War era when American soldiers brought samples back to the United States. Despite this cultural heritage, Thailand adopted strict cannabis prohibition in 1979 under the Narcotics Act B.E. 2522, classifying cannabis as a Category 5 narcotic with penalties including up to five years imprisonment for possession and up to 15 years for trafficking.

The prohibition regime remained largely unchanged for four decades, with Thailand maintaining one of Asia's strictest drug enforcement postures. Annual arrest figures for cannabis offenses ranged between 15,000 and 25,000 during the 2010s, with significant prison populations serving sentences for minor possession charges. The policy aligned Thailand with regional partners including Singapore, Malaysia, and Indonesia, all of which maintained capital punishment or lengthy prison terms for drug offenses.

Medical Legalization (2018-2022)

Thailand's first major policy shift occurred in December 2018 when the National Legislative Assembly amended the Narcotics Act to permit medical cannabis and kratom research. The amendment, which took effect in February 2019, reclassified cannabis extracts for medical and research purposes, though recreational use remained criminal. The Ministry of Public Health established a medical cannabis program allowing registered patients to access cannabis products through government hospitals and licensed pharmacies.

The medical framework initially proved highly restrictive. Only six government hospitals were authorized to dispense cannabis products during the first year, and patient eligibility was limited to cancer, epilepsy, and chemotherapy side effects. Cultivation licenses were granted exclusively to government agencies, universities, and a small number of community enterprises. The Narcotics Control Board maintained tight oversight, and THC content was capped at 0.2% for most products.

Between 2019 and 2021, the medical program expanded gradually. The Ministry of Public Health approved approximately 1,800 community enterprise cultivation licenses and 200 clinic dispensing licenses. The Government Pharmaceutical Organization began producing standardized cannabis oil extracts. Patient registrations grew to approximately 50,000 by late 2021, though access remained concentrated in urban areas with limited product variety.

Full Decriminalization (June 2022)

Thailand's most dramatic policy shift occurred on June 9, 2022, when the Ministry of Public Health removed cannabis and hemp from the Category 5 narcotics list entirely. The delisting, announced by Minister Anutin Charnvirakul, effectively decriminalized cannabis cultivation, possession, and consumption for adults nationwide. The policy change made Thailand the first Asian nation to decriminalize cannabis at the national level.

The decriminalization framework operated under the Public Health Act B.E. 2535 rather than narcotics law. The FDA required businesses to register cannabis activities but imposed minimal restrictions on retail sales, product types, or consumption venues. The only significant limitation was a prohibition on marketing cannabis for recreational use, though this restriction proved largely unenforceable. THC content limits were removed for most products, though smoking in public spaces technically remained subject to tobacco control regulations.

The policy created immediate market opportunities. Within 60 days of decriminalization, more than 3,000 businesses registered cannabis activities with the FDA. By December 2022, that number exceeded 6,000. Cannabis cafes opened across Bangkok, Chiang Mai, Phuket, and other tourist destinations. Dispensaries began selling high-THC flower, edibles, and concentrates with minimal regulatory oversight. Online delivery services proliferated. Cultivation licenses were granted to thousands of households and small farms.

Growing Opposition (2022-2025)

Political opposition to decriminalization emerged almost immediately. The Bhumjaithai Party, led by Minister Anutin, had championed decriminalization as part of its 2019 election platform, positioning cannabis as an economic development opportunity for rural farmers. However, coalition partners including the Democrat Party and Palang Pracharath Party expressed concerns about public health impacts and Thailand's international reputation.

In September 2022, the Ministry of Public Health proposed a Cannabis Control Act that would have established a comprehensive regulatory framework with licensing requirements, potency limits, and age restrictions. The draft legislation stalled in committee amid disagreements over whether to maintain decriminalization or return to a medical-only model. The Pheu Thai Party, which won the May 2023 general election, campaigned on a platform that included recriminalization of recreational cannabis.

Public health officials raised concerns about youth access and impaired driving. A Ministry of Public Health survey in late 2023 found that approximately 12% of Thai adolescents aged 15-18 reported trying cannabis since decriminalization, up from an estimated 3% under prohibition. Emergency room visits for cannabis-related acute intoxication increased by approximately 400% between 2021 and 2024, according to data from Siriraj Hospital and Ramathibodi Hospital in Bangkok.

Tourism industry stakeholders expressed mixed views. Some hotel and hospitality operators reported increased bookings from international cannabis tourists, particularly from countries with prohibition. However, family-oriented tourism businesses and conservative Muslim-majority southern provinces raised concerns about Thailand's image transformation. The Tourism Authority of Thailand conducted focus groups in key markets including China, Japan, and South Korea, finding negative perceptions among potential visitors concerned about drug normalization.

Legislative Push for Recriminalization (2025-2026)

The recriminalization effort gained momentum following the formation of a new coalition government in late 2025. The Pheu Thai-led coalition, which excluded the pro-cannabis Bhumjaithai Party, prioritized cannabis policy reform. In March 2026, the Ministry of Public Health announced it would draft legislation to restrict cannabis to medical use and reinstate criminal penalties for recreational possession.

The draft Cannabis Control Act, released for public comment in June 2026, proposed returning cannabis to the narcotics schedule while creating a parallel medical access framework. The legislation would establish criminal penalties of up to one year imprisonment and fines up to 20,000 baht (approximately $570 USD) for recreational possession of any amount. Cultivation without a medical license would carry penalties of up to five years imprisonment. The bill would grant the FDA authority to license medical cannabis producers, processors, and dispensaries under standards similar to pharmaceutical manufacturing requirements.

The draft legislation advanced to parliamentary committee review in July 2026, with floor votes expected in late 2026 or early 2027. The government has indicated it would provide a transition period of 90-180 days for businesses to wind down recreational operations or convert to medical-only models, though specific transition provisions remain under negotiation.

Key Players

Ministry of Public Health and FDA

The Ministry of Public Health, led by Minister Cholnan Srikaew, is the primary architect of recriminalization efforts. The Ministry oversees the Food and Drug Administration, which would administer medical cannabis licensing under the proposed framework. Minister Cholnan, a physician and member of the Pheu Thai Party, has stated that decriminalization was implemented "too quickly without adequate safeguards" and that a medical-only model better serves public health objectives. The FDA has indicated it would model medical cannabis regulations on existing pharmaceutical manufacturing standards, requiring Good Manufacturing Practice (GMP) certification, standardized potency testing, and physician prescription requirements.

Bhumjaithai Party and Anutin Charnvirakul

The Bhumjaithai Party, formerly the coalition partner responsible for decriminalization, now serves in opposition and has vowed to block recriminalization efforts. Party leader Anutin Charnvirakul, who served as Minister of Public Health when decriminalization was implemented, has called the recriminalization push "a betrayal of farmers and patients." Bhumjaithai holds approximately 70 seats in the 500-member House of Representatives and has threatened to filibuster the Cannabis Control Act. The party has proposed alternative legislation that would maintain decriminalization while adding age restrictions, potency limits, and marketing controls.

Thai Cannabis Industry Association

The Thai Cannabis Industry Association, formed in late 2022, represents approximately 2,000 businesses including cultivators, processors, and retailers. The association has lobbied against recriminalization, arguing that the industry supports 50,000 jobs and generates significant tax revenue. The group has proposed a self-regulatory framework modeled on alcohol industry practices, with voluntary age verification, responsible marketing guidelines, and product testing standards. Association representatives have warned that abrupt recriminalization could trigger lawsuits against the government for regulatory takings and breach of legitimate expectations.

Patient Advocacy Organizations

Medical cannabis patient groups, including the Thai Medical Cannabis Association and the Cannabis Patients Network, have expressed concerns that recriminalization could restrict access for legitimate medical users. These organizations represent an estimated 200,000 registered medical patients and have called for the draft legislation to include broad qualifying conditions, affordable pricing requirements, and protections against discrimination. Patient advocates have particularly emphasized the need for continued access to whole-plant cannabis products rather than pharmaceutical isolates, citing patient preferences for full-spectrum preparations.

International Investors and MSOs

North American multi-state operators including several Canadian licensed producers established Thai operations between 2022 and 2025, investing an estimated $200-300 million in cultivation facilities, processing infrastructure, and retail networks. These companies have engaged legal counsel to assess potential claims under bilateral investment treaties if recriminalization proceeds. Some operators have indicated they would pivot to medical-only operations if licensing requirements prove feasible, while others have begun exit planning. The uncertainty has effectively frozen new foreign investment in Thailand's cannabis sector since early 2026.

Legal and Regulatory Framework

Thailand's cannabis policy operates at the intersection of narcotics law, public health regulation, and administrative licensing, creating a complex legal landscape that the proposed recriminalization would fundamentally restructure.

Current Decriminalized Framework

Under the current regime established in June 2022, cannabis is not listed in the Narcotics Act B.E. 2522 schedules. Instead, cannabis activities are regulated under the Public Health Act B.E. 2535, which grants the Ministry of Public Health and FDA broad authority to regulate food, drugs, and health products. The FDA requires businesses engaged in cannabis cultivation, processing, or sales to register their activities through an online portal, but registration is largely automatic with minimal review.

The primary legal restriction is a prohibition on marketing cannabis for recreational use, codified in Ministry of Public Health Notification Re: Cannabis B.E. 2565. However, this restriction has proven difficult to enforce, as businesses can market products for "relaxation," "wellness," or "traditional medicine" without explicitly claiming recreational purposes. There are no THC potency limits for most products, no mandatory testing requirements, and no age restrictions beyond general prohibitions on sales to minors under tobacco and alcohol laws.

Smoking cannabis in public spaces is technically prohibited under the Non-Smokers' Health Protection Act B.E. 2535, which bans smoking in most public areas. However, enforcement has been inconsistent, and many cannabis cafes operate openly with designated consumption areas. Local governments have authority to impose additional restrictions, and some municipalities have banned cannabis businesses entirely, though such local prohibitions face legal challenges.

Proposed Medical-Only Framework

The draft Cannabis Control Act would return cannabis to Category 5 of the Narcotics Act while creating a parallel medical access system. The legislation would amend the Narcotics Act B.E. 2522 to add a new section specifically addressing medical cannabis, similar to frameworks in Germany, Australia, and Israel.

Under the proposed system, the FDA would issue three categories of licenses: cultivation, processing, and dispensing. Cultivation licenses would require applicants to demonstrate secure facilities, quality control systems, and compliance with Good Agricultural Practice (GAP) standards. Processing licenses would require GMP certification equivalent to pharmaceutical manufacturing standards. Dispensing licenses would be limited to pharmacies and medical clinics with licensed pharmacists or physicians on staff.

Medical access would require physician certification for qualifying conditions. The draft legislation does not specify qualifying conditions, instead delegating that authority to the Ministry of Public Health through administrative regulations. Patient advocates have expressed concern that the Ministry may adopt a narrow list limited to cancer, epilepsy, and chronic pain, excluding mental health conditions, sleep disorders, and other indications commonly treated under the current open-access system.

Criminal penalties for violations would include up to one year imprisonment and fines up to 20,000 baht for possession without medical authorization, up to five years for unlicensed cultivation, and up to 10 years for unlicensed commercial distribution. These penalties are less severe than pre-2018 prohibition but represent a significant escalation from the current decriminalized status.

Constitutional and Administrative Law Considerations

Legal scholars have raised questions about whether abrupt recriminalization could violate constitutional protections or administrative law principles. The Constitution of the Kingdom of Thailand B.E. 2560 (2017) includes provisions protecting legitimate expectations and prohibiting arbitrary government action. Businesses that invested in cannabis operations in reliance on the decriminalized framework may argue that recriminalization without adequate transition periods or compensation constitutes a violation of these protections.

The Administrative Procedure Act B.E. 2539 requires government agencies to provide notice and opportunity for comment before implementing regulations that significantly affect private interests. The Ministry of Public Health conducted a 30-day public comment period on the draft Cannabis Control Act in June-July 2026, receiving more than 15,000 submissions. However, critics argue that the comment period was insufficient given the magnitude of the policy change and that the Ministry has not adequately addressed stakeholder concerns in revised drafts.

International Treaty Obligations

Thailand is a party to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. These treaties require parties to limit cannabis to medical and scientific purposes and to establish criminal penalties for unauthorized cultivation and distribution. Thailand's 2022 decriminalization arguably violated these treaty obligations, though the government maintained that its regulatory framework satisfied treaty requirements by prohibiting recreational marketing.

Recriminalization would bring Thailand back into clear compliance with international treaty obligations. However, the medical-only framework would still require Thailand to establish controls consistent with treaty requirements, including licensing, record-keeping, and reporting to the International Narcotics Control Board (INCB). The INCB has not issued formal findings regarding Thailand's compliance status but has included Thailand in its annual reports as a jurisdiction of concern since 2022.

Market and Business Implications

Recriminalization would devastate Thailand's $1.2 billion cannabis industry, forcing thousands of businesses to close or restructure while creating potential opportunities for well-capitalized medical operators.

Retail and Hospitality Sector Impact

The most immediate casualties would be the estimated 4,000-5,000 cannabis dispensaries, cafes, and consumption lounges that emerged under decriminalization. These businesses, concentrated in Bangkok, Chiang Mai, Phuket, and Pattaya, generate an estimated $600-800 million in annual revenue. Most operate on thin margins with limited capital reserves and would be unable to meet GMP certification requirements or obtain medical dispensing licenses.

Cannabis cafes, which combine consumption lounges with food and beverage service, represent a particularly vulnerable segment. These establishments have become popular tourist destinations, with some venues reporting 60-70% international customer bases. Recriminalization would eliminate the recreational consumption model entirely, as medical frameworks do not typically permit on-site consumption. Industry analysts estimate that 80-90% of current retail and hospitality cannabis businesses would close under a medical-only regime.

Cultivation and Processing Sector

Thailand's cultivation sector includes an estimated 3,000-4,000 licensed growers ranging from small household operations to commercial farms of 10+ acres. Total cultivation area is estimated at 2,500-3,500 acres, producing approximately 15,000-20,000 kilograms of dried flower annually. Wholesale prices for premium flower have ranged from $800-1,200 per kilogram, supporting significant income for rural farming communities.

A medical-only framework would dramatically reduce demand. Medical markets typically consume 10-20% of the volume of open adult-use markets, based on data from jurisdictions that have transitioned from medical-only to adult-use systems. If Thailand's medical market follows similar patterns, cultivation demand could fall to 1,500-4,000 kilograms annually, supporting perhaps 300-600 licensed cultivators. Small household growers would be largely excluded, as medical licensing requirements favor larger operations with quality control infrastructure.

Processing and extraction businesses face similar contraction. The current market includes approximately 200-300 processors producing edibles, concentrates, topicals, and tinctures. Medical frameworks typically require pharmaceutical-grade processing facilities with GMP certification, cleanroom environments, and validated extraction methods. Industry consultants estimate that fewer than 20-30 current processors could meet these standards without substantial capital investment.

Investment and Capital Markets

Foreign investment in Thai cannabis ventures has largely frozen since recriminalization discussions intensified in late 2025. Several Canadian licensed producers that established cultivation partnerships have placed expansion plans on hold. U.S.-based ancillary service providers, including testing laboratories, security firms, and software platforms, have begun reducing Thai operations or seeking exits.

The uncertainty has created valuation challenges for existing investments. Private equity firms that invested in Thai cannabis companies at valuations based on recreational market potential now face significant write-downs. Some investors have engaged legal counsel to assess potential claims under bilateral investment treaties, particularly the Thailand-Canada Investment Agreement and the U.S.-Thailand Treaty of Amity and Economic Relations. However, legal experts note that investment treaty claims face high bars and lengthy timelines.

A medical-only market could attract different capital sources. Pharmaceutical companies and medical device manufacturers have expressed interest in Thai medical cannabis opportunities, particularly for export-oriented production. Thailand's tropical climate, low labor costs, and existing agricultural infrastructure could support cost-competitive medical cannabis production for export to markets including Germany, Australia, and Israel, all of which import medical cannabis. However, export opportunities would require Thailand to establish GMP certification programs recognized by importing jurisdictions, a process that typically takes 2-3 years.

Employment and Economic Development

The cannabis industry currently supports an estimated 50,000 jobs across cultivation, processing, retail, and ancillary services. These jobs are concentrated in tourist areas and rural farming communities, where alternative employment opportunities are limited. Recriminalization could eliminate 30,000-40,000 positions, based on the expected 70-80% reduction in business operations.

Rural farming communities face particular hardship. Cannabis cultivation has provided supplemental income for thousands of small farmers, particularly in northern provinces including Chiang Mai, Chiang Rai, and Nan. Average household income from cannabis cultivation has been estimated at 50,000-150,000 baht ($1,400-4,300 USD) annually, significant in regions where median household income is approximately 200,000 baht. The loss of this income stream could accelerate rural-to-urban migration and increase economic inequality.

What Experts Say

Public health officials, economists, and legal scholars have offered sharply divergent assessments of recriminalization, reflecting deep disagreements about the costs and benefits of Thailand's decriminalization experiment.

Dr. Sophon Mekthon, a public health professor at Mahidol University and former advisor to the Ministry of Public Health, has argued that decriminalization proceeded without adequate public health safeguards. According to Dr. Sophon's research published in the Journal of the Medical Association of Thailand, emergency room visits for cannabis-related acute intoxication increased from approximately 200 cases annually in 2021 to more than 1,000 cases in 2024. He has stated that the increase demonstrates the need for stricter controls, though he has also noted that serious adverse events remain rare and that many emergency room visits involve anxiety reactions rather than medical emergencies.

Economists have emphasized the fiscal implications of recriminalization. Dr. Somchai Jitsuchon, research director at the Thailand Development Research Institute, has estimated that the cannabis industry contributed approximately 15-20 billion baht ($430-570 million USD) to GDP in 2025 and generated 2-3 billion baht in tax revenue through value-added tax and business income tax. According to Dr. Somchai's analysis, recriminalization would eliminate most of this economic activity while creating enforcement costs estimated at 500-800 million baht annually for police, courts, and corrections. He has described the policy reversal as economically counterproductive and has suggested that a regulated adult-use framework would generate greater tax revenue while addressing public health concerns.

Legal scholars have raised concerns about the rule of law implications. Professor Prinya Thaewanarumitkul of Thammasat University's Faculty of Law has argued that abrupt recriminalization without transition provisions or compensation could violate constitutional protections against arbitrary government action. In testimony before the parliamentary committee reviewing the Cannabis Control Act, Professor Prinya stated that businesses invested in cannabis operations in reasonable reliance on the decriminalized framework and that the government has an obligation to provide adequate transition periods or financial compensation. He has proposed a minimum two-year transition period with government buyback programs for existing inventory and equipment.

Patient advocates have emphasized medical access concerns. Taopiphop Limjittrakorn, director of the Cannabis Patients Network, has stated that the proposed medical framework may exclude many patients currently using cannabis for conditions not recognized by Thailand's conservative medical establishment. According to patient surveys conducted by the organization, approximately 40% of current medical cannabis users treat mental health conditions including anxiety, depression, and PTSD, none of which are likely to be included in initial qualifying condition lists. Taopiphop has called for the legislation to include a broad qualifying condition list and a process for patients and physicians to petition for additional conditions.

International drug policy experts have viewed Thailand's reversal as a setback for harm reduction approaches. Dr. Kasia Malinowska-Sempruch, director of the Global Drug Policy Program at the Open Society Foundations, has described recriminalization as a missed opportunity to develop evidence-based cannabis policies suited to Asian contexts. She has noted that Thailand's decriminalization, despite implementation challenges, demonstrated that cannabis policy reform is politically viable in conservative societies and that reversal may discourage reform efforts in neighboring countries.

What's Next: Timeline and Scenarios

The Cannabis Control Act faces parliamentary review through late 2026 and early 2027, with implementation likely in mid-to-late 2027 if the legislation passes.

Legislative Calendar

The draft legislation is currently under review by the House of Representatives Committee on Public Health, which is expected to complete its assessment by October 2026. The committee has scheduled public hearings in Bangkok, Chiang Mai, and Phuket to gather stakeholder input. Following committee review, the bill would advance to a first reading in the full House of Representatives, likely in November or December 2026.

The Bhumjaithai Party has indicated it will use procedural tactics to delay floor votes, including requesting extended debate periods and proposing numerous amendments. However, the governing coalition holds approximately 320 seats in the 500-member House, sufficient to overcome procedural delays if members vote as a bloc. Parliamentary observers expect the bill to pass the House by early 2027.

Following House passage, the legislation would advance to the Senate, which has 250 members appointed through a complex selection process. The Senate has traditionally taken a conservative stance on social policy issues and is expected to support recriminalization. Senate review typically takes 60-90 days, suggesting final passage by mid-2027.

The legislation would then require royal assent and publication in the Royal Gazette before taking effect. The government has indicated it would include a transition period of 90-180 days, meaning full implementation would likely occur in late 2027 or early 2028.

Scenario Analysis

Several scenarios could alter this timeline or outcome. If the Bhumjaithai Party successfully delays floor votes beyond the current parliamentary session, the legislation could be postponed until after the next general election, which must occur by May 2027. A new election could reshuffle coalition dynamics and potentially bring Bhumjaithai back into government, though current polling suggests the Pheu Thai coalition would likely retain power.

Public opposition could also influence the legislative process. Cannabis industry associations have organized protests and petition campaigns, gathering more than 100,000 signatures opposing recriminalization. If public opposition intensifies, some coalition members may break ranks and vote against the legislation. However, political analysts consider this scenario unlikely given the coalition's strong majority and the Pheu Thai Party's campaign commitments.

A constitutional challenge represents another possibility. If the legislation passes, affected businesses could petition the Constitutional Court to review whether recriminalization violates constitutional protections. The Constitutional Court has authority to suspend implementation pending review, though it rarely exercises this power. Legal experts consider a successful constitutional challenge unlikely but note that the Court could require the government to provide more generous transition provisions or compensation.

International pressure could also play a role. The U.S. Chamber of Commerce and Canadian business associations have raised concerns about investment protections with Thai government officials. If foreign governments elevate these concerns to diplomatic channels, Thailand could face pressure to modify the legislation to protect existing investments. However, Thailand has historically prioritized domestic policy considerations over foreign investor concerns in social policy areas.

Implementation Challenges

Even if the legislation passes as drafted, implementation will face significant challenges. The FDA would need to develop detailed regulations for medical licensing, including application procedures, facility standards, testing requirements, and physician certification processes. This regulatory development typically takes 12-18 months.

Enforcement would require coordination among the FDA, the Narcotics Control Board, the Royal Thai Police, and local governments. Thailand's law enforcement agencies have limited experience with nuanced cannabis regulations, having operated under simple prohibition for decades. Training programs would be necessary to help officers distinguish between legal medical activities and criminal violations.

The transition period would create particular challenges. Businesses would need to liquidate inventory, terminate leases, and lay off employees within 90-180 days. Some operators have indicated they would simply abandon operations rather than conduct orderly wind-downs, potentially creating public safety issues with unsecured facilities and uncontrolled inventory. The government has not announced plans for inventory buyback programs or disposal assistance.

Further Reading

• Narcotics Act B.E. 2522 (1979) - https://www.fda.moph.go.th/sites/drug/SitePages/Law_Narcotics.aspx
• Ministry of Public Health Notification Re: Cannabis B.E. 2565 (2022) - https://www.fda.moph.go.th/sites/drug/SitePages/Cannabis.aspx
• Draft Cannabis Control Act (June 2026) - https://www.parliament.go.th/ewtadmin/ewt/parliament_parcy/ewt_news.php
• Thailand Development Research Institute: Economic Impact of Cannabis Decriminalization (2025) - https://tdri.or.th/en/
• Journal of the Medical Association of Thailand: Cannabis-Related Emergency Room Visits 2021-2024 - https://www.jmatonline.com/
• International Narcotics Control Board Annual Report 2025 - https://www.incb.org/incb/en/publications/annual-reports/annual-report-2025.html
• Constitution of the Kingdom of Thailand B.E. 2560 (2017) - https://www.constitutionalcourt.or.th/occ_en/download/article_20170410173022.pdf
• 1961 Single Convention on Narcotic Drugs - https://www.unodc.org/unodc/en/treaties/single-convention.html
• Thailand-Canada Investment Agreement - https://www.international.gc.ca/trade-commerce/trade-agreements-accords-commerciaux/agr-acc/thailand-thailande/fipa-apie/index.aspx
• U.S.-Thailand Treaty of Amity and Economic Relations - https://www.state.gov/u-s-relations-with-thailand/